According to Jazz Pharmaceuticals's latest financial reports the company has $1.36 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $0.88 B | 49.04% |
2021-12-31 | $0.59 B | -72.27% |
2020-12-31 | $2.13 B | 97.97% |
2019-12-31 | $1.07 B | 30.65% |
2018-12-31 | $0.82 B | 37.2% |
2017-12-31 | $0.60 B | 41.1% |
2016-12-31 | $0.42 B | -56.92% |
2015-12-31 | $0.98 B | 44.55% |
2014-12-31 | $0.68 B | 7.47% |
2013-12-31 | $0.63 B | 64.39% |
2012-12-31 | $0.38 B | 145.22% |
2011-12-31 | $0.15 B | 252.5% |
2010-12-31 | $44.79 M | 187.23% |
2009-12-31 | $15.59 M | -39.8% |
2008-12-31 | $25.9 M | -74.83% |
2007-12-31 | $0.10 B | 30.4% |
2006-12-31 | $78.94 M | 282.98% |
2005-12-31 | $20.61 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() Novartis NVS | $11.17 B | 720.23% | ๐จ๐ญ Switzerland |
![]() AmerisourceBergen
ABC | $1.38 B | 1.99% | ๐บ๐ธ USA |
![]() Endo International
ENDPQ | $0.86 B | -36.44% | ๐ฎ๐ช Ireland |
![]() Teva Pharmaceutical Industries TEVA | $2.66 B | 95.92% | ๐ฎ๐ฑ Israel |